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Dear Editor,
A 52-year-old man was admitted to
the intensive care unit (ICU) with
septic shock due to pneumonia. Two
months before he had an oesophago-
gastrectomy because of carcinoma of
the distal part of the oesophagus. The
post-operative course was compli-
cated because of ischaemic lesions in
the transverse colon and suture
dehiscence of the ileotransversos-
tomy. An ileostomy and colostomy
were constructed (Fig. 1).
Apart from antibiotic treatment,
he received selective decontamina-
tion of the digestive tract (SDD) as
described previously by De Smet
et al [1]. SDD was administered four
times daily as a 2% oral paste, con-
taining amphotericin B, tobramycin
and colistin. Four times daily a 10 ml
(containing 500 mg amphotericin B,
100 mg colistin, 80 mg tobramycin)
suspension was given nasogastrical-
ly. Additionally, twice daily a
suppository (containing 500 mg
amphotericin B, 40 mg tobramycin,
100 mg colistin) was administered in
the colostomy of the descending
colon. He recovered but because of
ICU-acquired weakness he needed
prolonged mechanical ventilation.
Thirty days after admission he
became oliguric and developed renal
failure with renal acidosis without
further clinical signs of haemody-
namic instability. His creatinine level
gradually increased from 50 to
263 lmol/l. Physical, laboratory and
radiological examination ruled out
sepsis, hypovolaemia and post-renal
obstruction. Medication-induced
nephrotoxicity was suspected. Serum
tobramycin level was elevated
(18.9 mg/l). SDD was discontinued.
After haemodialysis and veno-venous
haemoﬁltration tobramycin levels
became undetectable again. However,
renal insufﬁciency persisted and he
remained dependent on dialysis.
Elevated serum tobramycin levels
during SDD have been shown in
patients with normal renal function
and pre-existent renal insufﬁciency
[2, 3]. Several mechanisms might
explain increased serum levels of
Fig. 1 Schematic drawing of patient’s changed anatomy after surgery. Resection of
esophagus and stomach, replaced by a colon segment with a Roux-Y reconstruction. After
suture dehiscence of the ileotransversostomy the suture was opened, transversectomy was
performed because of multiple ischaemic lesions. An ileostomy and colostomy were
constructed
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in this patient. First, the integrity of
the mucosal barrier might have been
compromised by the initial sepsis
causing increased permeability for
tobramycin [4]. Secondly, our patient
was malnourished as a result of
chronic illness and frequent periods
of retention of enteral feeding. Mal-
nutrition is associated with increased
movements of large molecules
through the paracellular tight junction
in jejunal epithelia [5]. Thirdly, our
patient had a blinded jejunal loop
which could act as reservoir for
tobramycin.
The amphotericin B levels were
not measured but could also be
increased. The nephrotoxic effect of
parenteral administration of ampho-
tericin B is well known. No other
medication could explain the acute
renal failure.
This case indicates that patients
with altered abdominal anatomy and/
or perforations and/or malnutrition
might be at risk to develop nephro-
toxicity from SDD, especially when
SDD is administered via several
routes. Besides the current debate
about the effects of SDD on antibiotic
resistance, no complications of
tobramycin-related toxicity are
reported in more than 50 randomized
controlled trials. Future studies on
SDD should also incorporate such
safety analyses.
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